• About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
Friday, August 12, 2022
No Result
View All Result
  • Login
Rajesh Spinal Cord Injury
  • Home
  • Spinal Cord Injury
  • Rehabilitation
    •  Epidural Stimulation
  • Latest SCI News
  • Spine
  • Neuro
  • Health
  • Ayurveda
  • More
    • Diet-Nutrition
    • Healthy Recipes
    • Nutrition Supplements
    • Weight Loss
    • Yoga & Meditation
  • Home
  • Spinal Cord Injury
  • Rehabilitation
    •  Epidural Stimulation
  • Latest SCI News
  • Spine
  • Neuro
  • Health
  • Ayurveda
  • More
    • Diet-Nutrition
    • Healthy Recipes
    • Nutrition Supplements
    • Weight Loss
    • Yoga & Meditation
HealthNews
No Result
View All Result
Home Spine

Spine BioPharma Completes Series B Financing

admin by admin
March 31, 2022
in Spine
0
Spine BioPharma Completes Series B Financing

Proceeds Will Help Medical Development of SB-01 For Injection for Remedy of Degenerative Disc Illness

NEW YORK, March 28, 2022 /PRNewswire/ — Backbone BioPharma, Inc., a biopharmaceutical firm dedicated to growing non-opiate, non-surgical therapies for the therapy of ache and incapacity from continual low again ache attributable to degenerative disc illness, immediately introduced the completion of a $13 million Sequence B fairness financing. Present buyers Viscogliosi Bros., LLC, Cercano Administration, Pacira Biosciences and others participated within the financing. The corporate intends to make use of the financing to assist additional improvement of SB-01 For Injection “SB-01” (previously known as Remedisc™), a first-in-class therapeutic for the therapy of degenerative disc illness.

“We’re delighted to proceed to learn from the monetary assist and experience of our distinguished investor-partners, stated Backbone BioPharma CEO Marc Viscogliosi, “This Sequence B financing speaks to their confidence in our firm, and it’ll assist drive the analysis and improvement of SB-01, a novel therapeutic that gives a possible non-opiate, non-surgical therapy choice to continual low again ache sufferers.”

SB-01 is a 7-amino acid chain peptide that binds to and induces down regulation of remodeling development issue, beta 1 (TGFβ1), which is commonly extremely expressed within the degenerated discs of sufferers with decrease again ache. Overexpression of TGFβ1 signaling is related to irritation and the degradation of extracellular matrix which maintains the structural integrity of wholesome spinal discs. TGFβ1 additionally stimulates the expression of nerve development issue, resulting in a rise in sensory neurons and discogenic ache. SB-01 therapy of a diseased disc antagonizes the overexpression of TGFβ1, which decreases irritation and helps the manufacturing of extracellular matrix, sustaining the structural integrity of the disc, lowering ache and bettering ache associated incapacity.

Intradiscal injection of SB-01 in sufferers with degenerative disc illness (DDD) was developed as a first-in-class pharmacological method to treating continual again ache, whereas doubtlessly stopping development of disc degeneration by means of TGFβ1 modulation.

McDermott, Will & Emery, LLP is performing as authorized advisor to Backbone BioPharma in reference to the transaction.

About Degenerative Disc Illness

Roughly 266 million people world wide expertise degenerative disc illness (DDD), and its related continual low again ache annually. DDD of the lumbar, or decrease, backbone is a big reason behind incapacity on this planet and an incredible expense to the healthcare system. It’s related to a wide range of scientific signs, together with, weak point, low again ache and incapacity of various ranges of severity. There may be at the moment no therapy for the underlying reason behind DDD and present approaches are geared toward managing ache by means of a wide range of approaches that embody bodily remedy, chiropractic care, over-the-counter medicines like non-steroidal anti-inflammatory medicine (NSAIDS) or prescription opioids. For sufferers with average to extreme ache that persists chronically, therapy plans embody epidural steroid injections, nerve blocks, radiofrequency ablation or surgical intervention. Medical outcomes fluctuate and sometimes don’t present predictable profit. Given the substantial prices, ache, and incapacity related to DDD, and the present lack of an accepted remedy that would relieve ache and improve perform with the potential to mediate the development of DDD or obtain a regenerative impact might revolutionize the usual of care.

About Backbone BioPharma

Backbone BioPharma makes a speciality of non-surgical therapies that can scale back ache, restore perform and gradual or cease pathological spinal illness development with out the usage of opioids. Backbone BioPharma’s lead candidate, SB-01, is a first-in-class, therapeutic for the therapy of degenerative disc illness, providing scientific advantages of ache reduction, restoration of perform and potential prevention of illness development. SB-01 has additionally been referred to YH14618 by Yuhan Corp. and P2K by Ensol Biosciences. To study extra about Backbone BioPharma, go to www.spinebiopharma.com.

Contact:
Marc Viscogliosi
marc@spinebiopharma.com 
(212) 583-9700

SOURCE Backbone Biopharma, Inc

Share via:

0 Shares
  • Facebook 0
  • Twitter
  • Email
  • Copy Link
  • More
ShareTweetSendShare
Previous Post

Surgalign Holdings Announces Collaboration with Inteneural Networks, a Leading Developer of Artificial Intelligence for Clinical Neurosciences

Next Post

U.S. Spine Surgeon Dr. Todd Lanman Launches Advanced Disc Replacement Spinal Restoration Center, Pioneering Leading-Edge Motion Preservation Solutions

admin

admin

Related Posts

Dr. Sean McCance, Top NYC Spine Surgeon, Recognized as a 2022 Castle Connolly Top Doctor®
Spine

Dr. Sean McCance, Top NYC Spine Surgeon, Recognized as a 2022 Castle Connolly Top Doctor®

August 12, 2022
Zavation releases In-Vitro and In-Vivo Research Summary for its novel “LABYRINTH™”
Spine

Zavation releases In-Vitro and In-Vivo Research Summary for its novel “LABYRINTH™”

August 10, 2022
NuVasive Opens Singapore Experience Center for Asia-Pacific region
Spine

NuVasive Announces Departure of Chief Commercial Officer

August 10, 2022
AxioMed LLC Submits Final Module III to the FDA Becoming the First and Only Lumbar Viscoelastic Total Disc Replacement Company to Complete a USA IDE Clinical Trial
Spine

AxioMed LLC Submits Final Module III to the FDA Becoming the First and Only Lumbar Viscoelastic Total Disc Replacement Company to Complete a USA IDE Clinical Trial

August 10, 2022
Avail Reaches Significant Network Expansion Milestone with the Signing of its 50th MedTech Contract
Spine

Avail Reaches Significant Network Expansion Milestone with the Signing of its 50th MedTech Contract

August 5, 2022
Spine Surgery is the Gateway to the New OR Ecosystem: Can We Step Up?
Spine

Spine Surgery is the Gateway to the New OR Ecosystem: Can We Step Up?

August 4, 2022
Load More
Next Post
U.S. Spine Surgeon Dr. Todd Lanman Launches Advanced Disc Replacement Spinal Restoration Center, Pioneering Leading-Edge Motion Preservation Solutions

U.S. Spine Surgeon Dr. Todd Lanman Launches Advanced Disc Replacement Spinal Restoration Center, Pioneering Leading-Edge Motion Preservation Solutions

Discussion about this post

Recent News

Shocking Ashwagandha Side Effects that Everyone Should Know!

Shocking Ashwagandha Side Effects that Everyone Should Know!

August 12, 2022
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022
Wash. jury sides with Issaquah officers accused of excessive force that killed an Alzheimer’s patient

Wash. jury sides with Issaquah officers accused of excessive force that killed an Alzheimer’s patient

August 12, 2022
Spinal Cord Injury Pipeline: Insights, Emerging Therapies, Key

Spinal Cord Injury Pipeline: Insights, Emerging Therapies, Key

August 12, 2022

About


Rajeshspinalinjury.com is the latest “Spinal Cord Injury, Neuro, and Health” NEWS website. We’ll provide you with merely interesting content. 

Categories

  • Ayurveda
  • Diet & Nutrition
  • Health News
  • Healthy Recipes
  • Neuro
  • Nutrition Supplements
  • Spinal Cord Injury News
  • Spine
  • Weight Loss
  • Yoga & Meditation
No Result
View All Result

Recent News

Shocking Ashwagandha Side Effects that Everyone Should Know!

Shocking Ashwagandha Side Effects that Everyone Should Know!

August 12, 2022
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms of Condition

Rajeshspinalinjury © 2022 || All Right Reserved. Design by Rinku

No Result
View All Result
  • Home
  • Spinal Cord Injury
  •  Epidural Stimulation
  • Rehabilitation
  • Spinal Cord Injury News
  • Spine
  • Neuro
  • Ayurveda
  • Diet & Nutrition
  • Health News
    • Healthy Recipes
  • Nutrition Supplements
  • Yoga & Meditation
  • Weight Loss
  • About Us
  • Contact Us

Rajeshspinalinjury © 2022 || All Right Reserved. Design by Rinku

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
  • Facebook
  • Twitter
  • Email
  • Copy Link
  • More Networks
Share via
Facebook
Twitter
LinkedIn
Mix
Email
Print
Copy Link
Powered by Social Snap
Copy link
CopyCopied
Powered by Social Snap